| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 6458 |
Provisional Schedule
| Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6458 | 17 April 2025 - 20 May 2025 |
Project Team
| Project lead | scopingta@nice.org.uk |
Email enquiries
- If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 April 2025 | In progress. Scoping commencing |
| 11 April 2025 | This topic will now be progressed as a Multiple Technology Appraisal (MTA) alongside the following topic; Resmetirom for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6529] The Invitation to Participate (ITP) will now be issued week commencing 07 July 2025 and the MTA title and ID number is: Resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6458] |
| 12 December 2024 | Referral |
| 29 November 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 29 November 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual